(Tiper Stock Exchange) – Pierrela global provider of the pharmaceutical industry listed on Euronext Milan, has communicated that the period for exercising the option rights has ended relating to the offer under option of a maximum of 45,776,255 newly issued shares deriving from the capital increase under option. During the offer period, which began on 10 July 2023 and ended today, 7,648,996 option rights were exercised, valid for the subscription of 38,244,980 new shares, equal to the83.55% of the total new shares offeredfor a total value of 58,476,574.42 euros.
As already communicated, the shareholders Fin Posillipo and Bootes respectively subscribed 30,009,200 and 3,931,555 new shares, for a total amount of 51,895,414.40 euros (equal to approximately 65.55% and 8.58% respectively of the capital increase) of which 7,981,907.50 euros released by offsetting the receivables due from the shareholders to the company and 43,913. 506.90 euros paid in cash.
THE remaining 1,506,255 unexercised option rights, which give the right to subscribe for a maximum of 7,531,275 new shares, corresponding to 16.45% of the total number of new shares offered, for an equivalent value of 11,515,319.50 euros, will be offered on the Exchange by Pierrel, through the intermediary of Equita SIM, in the meetings of 26 and 27 July 2023, unless early closing. The unexercised rights will be offered on Euronext Milan with ISIN code IT0005555732.
The unexercised rights attribute the right to subscribe for the new shares to unit price of 1.529 euro, of which 0.138 euro to be allocated to capital and 1.391 euro to be allocated to share premium, in the ratio of 5 new shares for every 1 unopted right purchased.